 | Sunovion Pharmaceuticals Acquires Cynapsus Therapeutics for $841 Million |
2016
| Areas | Competition, Antitrust and Foreign Investment, Corporate and Commercial, Employment and Labour, Health Care Law, Intellectual Property , Litigation, Pensions, Tax |
Summary
Goodmans represented Suovian Pharmaceuticals Inc. (Sunovion) in connection with its acquisition by plan of arrangement of Cynapsus Therapeutics Inc. (Cynapsus) (NASDAQ: CYNA) (TSX: CTH) for approximately $841 million. The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion is headquartered in Marlborough, Massachusetts and is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a leading Japanese pharmaceutical company.
Cynapsus is a specialty central nervous system pharmaceutical company based in Toronto that has been developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's Disease.
